Home/Celldex Therapeutics/Tibor Keler, Ph.D.
TK

Tibor Keler, Ph.D.

Founder, Executive Vice President and Chief Scientific Officer

Celldex Therapeutics

Celldex Therapeutics Pipeline

DrugIndicationPhase
BarzolvolimabChronic Spontaneous Urticaria (CSU)Phase 3
CDX-0159Prurigo Nodularis (PN)Phase 2
CDX-1140Oncology (Solid Tumors)Phase 1/2
CDX-527Oncology (Solid Tumors)Phase 1
CDX-622Inflammatory DiseasesPhase 1
CDX-585Oncology (Solid Tumors)Preclinical